Trial Profile
Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jun 2021
Price :
$35
*
At a glance
- Drugs Granisetron (Primary) ; Granisetron (Primary) ; Ondansetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 01 Jan 2021 Primary endpoint has been met. (Response to Anti-Emetic Therapy)
- 01 Jan 2021 Results published in the Supportive Care in Cancer
- 09 Oct 2019 Status changed from active, no longer recruiting to completed.